vs
Side-by-side financial comparison of GLOBAL PARTNERS LP (GLP) and Viatris (VTRS). Click either name above to swap in a different company.
Viatris is the larger business by last-quarter revenue ($3.7B vs $2.2B, roughly 1.7× GLOBAL PARTNERS LP). On growth, GLOBAL PARTNERS LP posted the faster year-over-year revenue change (7.0% vs 5.0%). Viatris produced more free cash flow last quarter ($619.3M vs $62.2M). Over the past eight quarters, Viatris's revenue compounded faster (0.5% CAGR vs 0.2%).
Global Partners LP is an American energy supply company ranked 361 in the 2018 Fortune 500. The company is organized as a master limited partnership, and its operations focus on the importing of petroleum products and marketing them in North America. It wholesales products like crude oil, diesel oil, gasoline, heating oil and kerosene.
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
GLP vs VTRS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.2B | $3.7B |
| Net Profit | $25.1M | — |
| Gross Margin | 11.9% | 31.1% |
| Operating Margin | 2.6% | -5.2% |
| Net Margin | 1.1% | — |
| Revenue YoY | 7.0% | 5.0% |
| Net Profit YoY | 5.0% | — |
| EPS (diluted) | — | $-0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.2B | $3.7B | ||
| Q3 25 | $2.2B | $3.7B | ||
| Q2 25 | $2.1B | $3.6B | ||
| Q1 25 | $2.2B | $3.2B | ||
| Q4 24 | $2.1B | $3.5B | ||
| Q3 24 | $2.1B | $3.7B | ||
| Q2 24 | $2.3B | $3.8B | ||
| Q1 24 | $2.2B | $3.7B |
| Q4 25 | $25.1M | — | ||
| Q3 25 | $29.0M | — | ||
| Q2 25 | $25.2M | — | ||
| Q1 25 | $18.7M | — | ||
| Q4 24 | $23.9M | — | ||
| Q3 24 | $45.9M | — | ||
| Q2 24 | $46.1M | — | ||
| Q1 24 | $-5.6M | — |
| Q4 25 | 11.9% | 31.1% | ||
| Q3 25 | 12.1% | 36.6% | ||
| Q2 25 | 13.1% | 37.3% | ||
| Q1 25 | 11.7% | 35.8% | ||
| Q4 24 | 13.0% | 34.6% | ||
| Q3 24 | 13.4% | 39.0% | ||
| Q2 24 | 12.6% | 38.2% | ||
| Q1 24 | 9.8% | 41.2% |
| Q4 25 | 2.6% | -5.2% | ||
| Q3 25 | 2.7% | 4.8% | ||
| Q2 25 | 2.9% | 6.5% | ||
| Q1 25 | 2.6% | -88.9% | ||
| Q4 24 | 2.8% | -5.1% | ||
| Q3 24 | 3.9% | 6.0% | ||
| Q2 24 | 3.7% | -6.3% | ||
| Q1 24 | 1.2% | 5.6% |
| Q4 25 | 1.1% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 0.9% | — | ||
| Q4 24 | 1.2% | — | ||
| Q3 24 | 2.1% | — | ||
| Q2 24 | 2.0% | — | ||
| Q1 24 | -0.3% | — |
| Q4 25 | — | $-0.34 | ||
| Q3 25 | — | $-0.11 | ||
| Q2 25 | — | $0.00 | ||
| Q1 25 | — | $-2.55 | ||
| Q4 24 | — | $-0.43 | ||
| Q3 24 | — | $0.08 | ||
| Q2 24 | — | $-0.27 | ||
| Q1 24 | — | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $1.3B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $14.7B |
| Total Assets | $3.9B | $37.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $975.3M | ||
| Q2 25 | — | $566.4M | ||
| Q1 25 | — | $755.0M | ||
| Q4 24 | — | $734.8M | ||
| Q3 24 | — | $1.9B | ||
| Q2 24 | — | $917.2M | ||
| Q1 24 | — | $1.0B |
| Q4 25 | — | $14.7B | ||
| Q3 25 | — | $15.2B | ||
| Q2 25 | — | $15.6B | ||
| Q1 25 | — | $15.7B | ||
| Q4 24 | — | $18.6B | ||
| Q3 24 | — | $19.8B | ||
| Q2 24 | — | $19.5B | ||
| Q1 24 | — | $20.0B |
| Q4 25 | $3.9B | $37.2B | ||
| Q3 25 | $3.7B | $37.9B | ||
| Q2 25 | $3.8B | $38.4B | ||
| Q1 25 | $3.8B | $38.5B | ||
| Q4 24 | $3.8B | $41.5B | ||
| Q3 24 | $3.7B | $44.8B | ||
| Q2 24 | $3.8B | $45.3B | ||
| Q1 24 | $3.5B | $47.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $101.0M | $815.8M |
| Free Cash FlowOCF − Capex | $62.2M | $619.3M |
| FCF MarginFCF / Revenue | 2.8% | 16.8% |
| Capex IntensityCapex / Revenue | 1.8% | 5.3% |
| Cash ConversionOCF / Net Profit | 4.03× | — |
| TTM Free Cash FlowTrailing 4 quarters | $193.3M | $1.9B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $101.0M | $815.8M | ||
| Q3 25 | $19.0M | $744.9M | ||
| Q2 25 | $216.3M | $219.7M | ||
| Q1 25 | $-51.6M | $535.5M | ||
| Q4 24 | $67.2M | $482.7M | ||
| Q3 24 | $122.7M | $826.5M | ||
| Q2 24 | $24.3M | $379.1M | ||
| Q1 24 | $-182.7M | $614.6M |
| Q4 25 | $62.2M | $619.3M | ||
| Q3 25 | $-678.0K | $658.1M | ||
| Q2 25 | $201.3M | $166.8M | ||
| Q1 25 | $-69.5M | $492.9M | ||
| Q4 24 | $20.4M | $342.3M | ||
| Q3 24 | $98.4M | $749.5M | ||
| Q2 24 | $8.7M | $320.3M | ||
| Q1 24 | $-199.3M | $564.8M |
| Q4 25 | 2.8% | 16.8% | ||
| Q3 25 | -0.0% | 17.6% | ||
| Q2 25 | 9.7% | 4.7% | ||
| Q1 25 | -3.2% | 15.2% | ||
| Q4 24 | 1.0% | 9.7% | ||
| Q3 24 | 4.6% | 20.1% | ||
| Q2 24 | 0.4% | 8.5% | ||
| Q1 24 | -9.0% | 15.5% |
| Q4 25 | 1.8% | 5.3% | ||
| Q3 25 | 0.9% | 2.3% | ||
| Q2 25 | 0.7% | 1.5% | ||
| Q1 25 | 0.8% | 1.3% | ||
| Q4 24 | 2.3% | 4.0% | ||
| Q3 24 | 1.1% | 2.1% | ||
| Q2 24 | 0.7% | 1.6% | ||
| Q1 24 | 0.8% | 1.4% |
| Q4 25 | 4.03× | — | ||
| Q3 25 | 0.66× | — | ||
| Q2 25 | 8.58× | — | ||
| Q1 25 | -2.76× | — | ||
| Q4 24 | 2.82× | — | ||
| Q3 24 | 2.67× | — | ||
| Q2 24 | 0.53× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GLP
| Gasoline | $1.0B | 46% |
| Refined Petroleum Products Renewable Fuels Crude Oil And Propane | $884.7M | 40% |
| Commercial Segment | $187.6M | 8% |
| Station Operations | $110.5M | 5% |
VTRS
| Brands | $1.2B | 32% |
| Generics | $1.1B | 29% |
| Lipitor | $377.3M | 10% |
| Norvasc | $175.2M | 5% |
| Other | $136.6M | 4% |
| Lyrica | $119.8M | 3% |
| Viagra | $104.2M | 3% |
| Creon | $98.9M | 3% |
| Epi Pen Auto Injectors | $79.0M | 2% |
| Yupelri | $70.6M | 2% |
| Effexor | $68.1M | 2% |
| Zoloft | $66.8M | 2% |
| Celebrex | $66.2M | 2% |
| Xalabrands | $42.0M | 1% |
| Dymista | $38.6M | 1% |
